Challenges in the scale-up of opioid substitution treatment in India.
作者信息
Ambekar Atul, Murthy Pratima, Basu Debasish, Rao G Prasad, Mohan Ashwin
机构信息
NDDTC, AIIMS, New Delhi, India.
Addictive Disorder Specialty Section, Indian Psychiatric Society, India.
出版信息
Indian J Psychiatry. 2017 Jan-Mar;59(1):6-9. doi: 10.4103/psychiatry.IndianJPsychiatry_14_17.
Abstract
摘要
相似文献
1
Challenges in the scale-up of opioid substitution treatment in India.
Indian J Psychiatry. 2017 Jan-Mar;59(1):6-9. doi: 10.4103/psychiatry.IndianJPsychiatry_14_17.
2
Scale-up of opioid substitution therapy in India: opportunities and challenges.
Int J Drug Policy. 2012 Mar;23(2):169-70. doi: 10.1016/j.drugpo.2011.11.002. Epub 2012 Jan 26.
3
Implementing opioid substitution in Lebanon: Inception and challenges.
Int J Drug Policy. 2016 May;31:178-83. doi: 10.1016/j.drugpo.2016.02.015. Epub 2016 Feb 23.
4
Opioid substitution treatment in Tihar prisons, India: Process of implementation.
Int J Drug Policy. 2015 Sep;26(9):890-1. doi: 10.1016/j.drugpo.2015.05.016. Epub 2015 Jun 6.
5
Tramadol for maintenance in opioid dependence: A retrospective chart review.
J Opioid Manag. 2017 Sep/Oct;13(5):329-334. doi: 10.5055/jom.2017.0401.
6
Substance, structure and stigma: parents in the UK accounting for opioid substitution therapy during the antenatal and postnatal periods.
Int J Drug Policy. 2013 Nov;24(6):e35-42. doi: 10.1016/j.drugpo.2013.04.004. Epub 2013 May 18.
7
Opioid substitution treatment in a public health setting: a collaboration between hospitals and NGOs in the Punjab.
Int J Drug Policy. 2012 Mar;23(2):170-1. doi: 10.1016/j.drugpo.2011.11.003. Epub 2012 Jan 9.
8
Substitution pharmacotherapies for opioid addiction: from methadone to LAAM and buprenorphine.
J Psychoactive Drugs. 1994 Apr-Jun;26(2):119-28. doi: 10.1080/02791072.1994.10472259.
9
Comparison of efficacy between buprenorphine and tramadol in the detoxification of opioid (heroin)-dependent subjects.
J Opioid Manag. 2013 Jan-Feb;9(1):35-41. doi: 10.5055/jom.2013.0145.
引用本文的文献
1
Trajectories of medication for opioid use disorder and their impact on HIV testing among people who inject drugs in India: A longitudinal assessment of clinic-based data.
Addiction. 2025 Apr;120(4):745-755. doi: 10.1111/add.16713. Epub 2024 Nov 27.
2
Expanding single-venue services to better engage young people who inject drugs: insights from India.
Harm Reduct J. 2024 Sep 14;21(1):170. doi: 10.1186/s12954-024-01084-w.
3
HIV, hepatitis B & C in people who inject drugs in India: A systematic review of regional heterogeneity & overview of opioid substitution treatment.
Indian J Med Res. 2023 Nov 1;158(5&6):522-534. doi: 10.4103/ijmr.ijmr_1930_23. Epub 2024 Jan 24.
4
Buprenorphine treatment receipt characteristics and retention among people who inject drugs at Integrated Care Centers in India.
Drug Alcohol Depend. 2023 May 1;246:109839. doi: 10.1016/j.drugalcdep.2023.109839. Epub 2023 Mar 20.
5
Medicolegal Issues with Reference to NDPS and MHCA in Management and Rehabilitation of Persons with Substance Use Disorders.
Indian J Psychiatry. 2022 Mar;64(Suppl 1):S146-S153. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_724_21. Epub 2022 Mar 22.
6
Relapse in opioid dependence: Role of psychosocial factors.
Indian J Psychiatry. 2021 Jul-Aug;63(4):372-376. doi: 10.4103/psychiatry.IndianJPsychiatry_383_20. Epub 2021 Aug 7.
7
Yoga as an Adjunct for Management of Opioid Dependence Syndrome: A Nine-Month Follow-Up Case Report.
Case Rep Psychiatry. 2021 Jul 23;2021:5541995. doi: 10.1155/2021/5541995. eCollection 2021.
8
Retention and outcomes for clients attending a methadone clinic in a resource-constrained setting: a mixed methods prospective cohort study in Imphal, Northeast India.
Harm Reduct J. 2020 Sep 29;17(1):68. doi: 10.1186/s12954-020-00413-z.
9
Clinical profile and outcomes of opioid abuse gastroenteropathy: an underdiagnosed disease entity.
Intest Res. 2020 Apr;18(2):238-244. doi: 10.5217/ir.2019.00104. Epub 2020 Feb 25.
10
Buprenorphine-based opioid substitution therapy in India: A few observations, thoughts, and opinions.
Indian J Psychiatry. 2018 Jul-Sep;60(3):361-366. doi: 10.4103/psychiatry.IndianJPsychiatry_218_17.
本文引用的文献
1
Adherence to Buprenorphine Maintenance Treatment in Opioid Dependence Syndrome: A Case Control Study.
Indian J Psychol Med. 2015 Jul-Sep;37(3):330-2. doi: 10.4103/0253-7176.162951.
2
Methadone maintenance treatment programme reduces criminal activity and improves social well-being of drug users in China: a systematic review and meta-analysis.
BMJ Open. 2015 Jan 8;5(1):e005997. doi: 10.1136/bmjopen-2014-005997.
3
Delivery models of opioid agonist maintenance treatment in South Asia: a good beginning.
Bull World Health Organ. 2013 Feb 1;91(2):150-3. doi: 10.2471/BLT.12.111815.
4
Does buprenorphine maintenance improve the quality of life of opioid users?
Indian J Med Res. 2013 Jan;137(1):130-5.
5
The availability, diversion and injection of pharmaceutical opioids in South Asia.
Drug Alcohol Rev. 2011 May;30(3):246-54. doi: 10.1111/j.1465-3362.2011.00304.x.
6
Oral naltrexone maintenance treatment for opioid dependence.
Cochrane Database Syst Rev. 2011 Apr 13;2011(4):CD001333. doi: 10.1002/14651858.CD001333.pub4.
7
HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage.
Lancet. 2010 Mar 20;375(9719):1014-28. doi: 10.1016/S0140-6736(10)60232-2. Epub 2010 Feb 26.
8
Pharmacologic treatments for opioid dependence: detoxification and maintenance options.
Dialogues Clin Neurosci. 2007;9(4):455-70. doi: 10.31887/DCNS.2007.9.2/hkleber.
9
Outpatient treatment engagement and abstinence rates following inpatient opioid detoxification.
J Addict Dis. 2006;25(4):27-35. doi: 10.1300/J069v25n04_03.
10
Outpatient maintenance/detoxification comparison of methadone and buprenorphine.
NIDA Res Monogr. 1989;95:384.
Zotero 插件